Allakos Incis A Clinical Stage Biotechnology Company Founded In 2012 And Headquartered In Redwood Citycaliforniathe Company Focuses On Developing Therapeutic Antibodies That Target Immunomodulatory Receptors On Immune Effector Cellswhich Are Involved In Various Allergicinflammatoryand Proliferative Diseases Allakos Is Dedicated To Advancing Its Drug Candidates Through Preclinical Studies And Clinical Trialsnotable Candidates Include Ak006A Monoclonal Antibody Targeting Siglec 6 For Conditions Like Atopic Dermatitiswhich Entered Phase 1 Trials In 2023Lirentelimabak002Targets Siglec 8 And Was Initially Developed For Eosinophilic Gastrointestinal Diseasesthough Its Development Has Been Pausedadditionallyak007 Is Being Explored For Immuno Oncology Applicationsallakos Aims To Improve Patient Outcomes By Developing Innovative Therapies For Complex Medical Conditions
